6533b82dfe1ef96bd1291d92

RESEARCH PRODUCT

Transarterial chemoembolization and sorafenib in hepatocellular carcinoma

Rodolfo SaccoMichela AntonucciGennaro Gadaleta-caldarolaGiancarlo MazzaGiovanni GalatiGiuseppe LombardiSilvia TremosiniGiuseppe Cabibbo

subject

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCombination therapyPopulationAntineoplastic AgentsSystemic therapyInternal medicinemedicineHumansPharmacology (medical)Chemoembolization TherapeuticeducationTherapeutic strategyClinical Trials as Topiceducation.field_of_studybusiness.industryPhenylurea CompoundsLiver NeoplasmsSorafenibmedicine.diseaseClinical trialOncologyHepatocellular carcinomaConcomitantRadiologybusinessmedicine.drug

description

Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this group of patients.

yearjournalcountryeditionlanguage
2014-05-23Expert Review of Anticancer Therapy
https://doi.org/10.1586/14737140.2014.920694